Microbiological Transformation of Ginsenoside Rg_1

Forty-nine microbial strains were used to screen their ability for the microbiological transforma-tion of ginsenoside Rg1. Aspergillus niger (3.1858) and Absidia coerulea (3.3538) were found to convert ginsenoside Rg1 efficiently to less polar metabolites. Preparative scale transformation with both fungi Absidia coerulea (3.3538) and Aspergillus niger (3.1858) have resulted in the production of one same metabolite (MT1). Its structure was char-acterized as 6-O-b-D-glucopyranosyl-20(S)-protopanaxatriol (Ginsenoside Rh1) on the basis of its TOF-MS and 1H, 13C NMR spectral data. The biotransformation kinetic curves for Ginsenoside Rg1 and MT1 were reported for the first time, and the biotransformation pathway was proposed.

Ginsenoside Rg_1 reduced the invasion of S.aureus into respiratory epithelial cells involving pro-inflammatory cytokines and glucocorticoid receptor

The invasion of Staphylococcus aureus into respiratory epithelial cells and the followed inflammatory responses cause serious tissue damage.The aim of this study was to investigate the effects of ginsenoside Rg_1（Rg_1）on S.aureus infection in vitro and its action mechanism.An internalization model was constructed to determine the effect of Rg_1 on S.aureus invasion. The changes of expression of integrinβ1,NF-κB and glucocorticoid receptor were analyzed by Western blot.Expression of pro-inflammatory genes was validated using RT-PCR.The results demonstrated that Rg_1 treatment could reduce the invasion of S.aureus into rat pulmonary epithelial cells by down-regulating integrinβ1.Its anti-inflammatory action was exerted through reducing NF-κB and expressions of intercellular adhesion molecule-1（ICAM-1）,tumor necrosis factor-α（TNF-α）,interleukin-2 （IL-2）and interleukin-6（IL-6）.The increased expression of glucocorticoid receptor was involved in this regulation.The results suggested that Rg_1 could play a positive role in reducing S.aureus infections.Rg_1 could be used for the treatment of S.aureus infection,potentially.

Ginsenoside Rb1 induces hepatic stellate cell ferroptosis to alleviate liver fibrosis via the BECN1/SLC7A11 axis

Liver fibrosis is primarily driven by the activation of hepatic stellate cells(HSCs),a process associated with ferroptosis.Ginsenoside Rb1(GRb1),a major active component extracted from Panax ginseng,inhibits HSC activation.However,the potential role of GRb1 in mediating HSC ferroptosis remains unclear.This study examined the effect of GRb1 on liver fibrosis both in vivo and in vitro,using CCl4-induced liver fibrosis mouse model and primary HSCs,LX-2 cells.The findings revealed that GRb1 effectively inactivated HSCs in vitro,reducing alpha-smooth muscle actin(a-SMA)and type I collagen(Col1A1)levels.Moreover,GRb1 significantly alleviated CCl4-induced liver fibrosis in vivo.From a mechanistic standpoint,the ferroptosis pathway appeared to be central to the antifibrotic effects of GRb1.Specifically,GRb1 promoted HSC ferroptosis both in vivo and in vitro,characterized by increased glutathione depletion,malondialdehyde production,iron overload,and accumulation of reactive oxygen species(ROS).Intriguingly,GRb1 increased Beclin 1(BECN1)levels and decreased the System Xc-key subunit SLC7A11.Further experiments showed that BECN1 silencing inhibited GRb1-induced effects on HSC ferroptosis and mitigated the reduction of SLC7A11 caused by GRb1.Moreover,BECN1 could directly interact with SLC7A11,initiating HSC ferroptosis.In conclusion,the suppression of BECN1 counteracted the effects of GRb1 on HSC inactivation both in vivo and in vitro.Overall,this study highlights the novel role of GRb1 in inducing HSC ferroptosis and promoting HSC inactivation,at least partly through its modulation of BECN1 and SLC7A11.

GPCR-Gs mediates the protective effects of ginsenoside Rb1 against oxygen-glucose deprivation/re-oxygenation-induced astrocyte injury

Objectives:To investigate whether the protective actions of ginsenoside Rb1(Rb1)on astrocytes are mediated through the G_(s)-type G-protein-coupled receptor(GPCR-G_(s)).Methods:Primary astrocyte cultures derived from neonatal mouse brain were used.Astrocyte injury was induced via oxygen-glucose deprivation/re-oxygenation(OGD/R).Cell morphology,viability,lactate dehydrogenase(LDH)leakage,apoptosis,glutamate uptake,and brain-derived neurotrophic factor(BDNF)secretion were assessed to gauge cell survival and functionality.Western blot was used to investigate the cyclic adenosine monophosphate(cAMP)and protein kinase B(Akt)signaling pathways.GPCR-G_(s)-specific inhibitors and molecular docking were used to identify target receptors.Results:Rb1 at concentrations ranging from 0.8 to 5μM did not significantly affect the viability,glutamate uptake,or BDNF secretion in normal astrocytes.OGD/R reduced astrocyte viability,increasing their LDH leakage and apoptosis rate.It also decreased glutamate uptake and BDNF secretion by these cells.Rb1 had protective effects of astrocytes challenged by OGD/R,by improving viability,reducing apoptosis,and enhancing glutamate uptake and BDNF secretion.Additionally,Rb1 activated the cAMP and Akt pathways in these cells.When the GPCR-G_(s) inhibitor NF449 was introduced,the protective effects of Rb1 completely disappeared,and its activation of cAMP and Akt signaling pathways was significantly inhibited.Conclusion:Rb1 protects against astrocytes from OGD/R-induced injury through GPCR-G_(s) mediation.

Crosstalk among Oxidative Stress,Autophagy,and Apoptosis in the Protective Effects of Ginsenoside Rb1 on Brain Microvascular Endothelial Cells:A Mixed Computational and Experimental Study

Objective Brain microvascular endothelial cells (BMECs) were found to shift from their usually inactive state to an active state in ischemic stroke (IS) and cause neuronal damage. Ginsenoside Rb1 (GRb1),a component derived from medicinal plants,is known for its pharmacological benefits in IS,but its protective effects on BMECs have yet to be explored. This study aimed to investigate the potential protective effects of GRb1 on BMECs. Methods An in vitro oxygen-glucose deprivation/reperfusion (OGD/R) model was established to mimic ischemia-reperfusion (I/R) injury. Bulk RNA-sequencing data were analyzed by using the Human Autophagy Database and various bioinformatic tools,including gene set enrichment analysis (GSEA),Gene Ontology (GO) classification and enrichment analysis,Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis,protein-protein interaction network analysis,and molecular docking. Experimental validation was also performed to ensure the reliability of our findings. Results Rb1 had a protective effect on BMECs subjected to OGD/R injury. Specifically,GRb1 was found to modulate the interplay between oxidative stress,apoptosis,and autophagy in BMECs. Key targets such as sequestosome 1 (SQSTM1/p62),autophagy related 5 (ATG5),and hypoxia-inducible factor 1-alpha (HIF-1α) were identified,highlighting their potential roles in mediating the protective effects of GRb1 against IS-induced damage. Conclusion GRbl protects BMECs against OGD/R injury by influencing oxidative stress,apoptosis,and autophagy. The identification of SQSTM1/p62,ATG5,and HIF-1α as promising targets further supports the potential of GRb1 as a therapeutic agent for IS,providing a foundation for future research into its mechanisms and applications in IS treatment.

A novel cabazitaxel liposomes modified with ginsenoside Rk1 for cancer targeted therapy

Objective:In this study,we aim to enhance the anti-prostate cancer efficacy of cabazitaxel(CTX)and reduce its immunosuppression and systemic toxicity by developing CTX-loaded liposomes modified with ginsenoside Rk1(Rk1/CTX-Lip).Methods:Physical and chemical properties of Rk1/CTX-Lip were investigated.We evaluated the biological functions of Rk1/CTXLip,both in vitro and in vivo.A subcutaneous prostate cancer(RM-1)-bearing mouse model was established to study the efficacy of Rk1/CTX-Lip inhibition in tumors.Simultaneously,a Candida albicans infection model was established in tumor-bearing mice to study the infection-relieving efficacy of Rk1/CTX-Lip.Finally,biocompatibility and in vivo safety of Rk1/CTX-Lip were evaluated.Results:We successfully prepared Rk1/CTX-Lip,achieving high CTX encapsulation efficiency(97.24±0.75)%and physical stability.Rk1/CTX-Lip demonstrated evasion of macrophage phagocytosis,effective tumor tissue targeting,and a significant reduction(>50%)in average tumor volume compared with Chol/CTX-Lip.Moreover,it relieved the concurrent infection burden and effectively regulated immune organs and cells,demonstrating superior biocompatibility.Conclusion:Rk1/CTX-Lip presents a promising new therapy for prostate cancer and holds potential for relieving concurrent fungal infections in cancer patients with low immunity.

Effect of ginsenoside Rg1 on hematopoietic stem cells in treating aplastic anemia in mice via MAPK pathway

BACKGROUND Aplastic anemia(AA)presents a significant clinical challenge as a life-threatening condition due to failure to produce essential blood cells,with the current the-rapeutic options being notably limited.AIM To assess the therapeutic potential of ginsenoside Rg1 on AA,specifically its protective effects,while elucidating the mechanism at play.METHODS We employed a model of myelosuppression induced by cyclophosphamide(CTX)in C57 mice,followed by administration of ginsenoside Rg1 over 13 d.The invest-igation included examining the bone marrow,thymus and spleen for pathological changes via hematoxylin-eosin staining.Moreover,orbital blood of mice was collected for blood routine examinations.Flow cytometry was employed to identify the impact of ginsenoside Rg1 on cell apoptosis and cycle in the bone marrow of AA mice.Additionally,the study further evaluated cytokine levels with enzyme-linked immunosorbent assay and analyzed the expression of key proteins in the MAPK signaling pathway via western blot.RESULTS Administration of CTX led to significant damage to the bone marrow’s structural integrity and a reduction in hematopoietic cells,establishing a model of AA.Ginsenoside Rg1 successfully reversed hematopoietic dysfunction in AA mice.In comparison to the AA group,ginsenoside Rg1 provided relief by reducing the induction of cell apoptosis and inflammation factors caused by CTX.Furthermore,it helped alleviate the blockade in the cell cycle.Treatment with ginsenoside Rg1 significantly alleviated myelosuppression in mice by inhibiting the MAPK signaling pathway.CONCLUSION This study suggested that ginsenoside Rg1 addresses AA by alleviating myelosuppression,primarily through modulating the MAPK signaling pathway,which paves the way for a novel therapeutic strategy in treating AA,highlighting the potential of ginsenoside Rg1 as a beneficial intervention.

Ginsenoside Rb1 improves energy metabolism after spinal cord injury

Mitochondrial damage caused by oxidative stress and energy deficiency induced by focal ischemia and hypoxia are important factors that aggravate diseases.Studies have shown that ginsenoside Rb1 has neurotrophic and neuroprotective effects.However,whether it influences energy metabolism after spinal cord injury remains unclear.In this study,we treated mouse and cell models of spinal cord injury with ginsenoside Rb1.We found that ginsenoside Rb1 remarkably inhibited neuronal oxidative stress,protected mitochondria,promoted neuronal metabolic reprogramming,increased glycolytic activity and ATP production,and promoted the survival of motor neurons in the anterior horn and the recovery of motor function in the hind limb.Because sirtuin 3 regulates glycolysis and oxidative stress,mouse and cell models of spinal cord injury were treated with the sirtuin 3 inhibitor 3-TYP.When Sirt3 expression was suppressed,we found that the therapeutic effects of ginsenoside Rb1 on spinal cord injury were remarkably inhibited.Therefore,ginsenoside Rb1 is considered a potential drug for the treatment of spinal cord injury,and its therapeutic effects are closely related to sirtuin 3.

Ginsenoside Rg1 protects against ischemia-induced neuron damage by regulating the rno-miRNA-27a-3p/PPARγaxis

A preliminary miRNA screening showed that expression levels of rno-miRNA-27a-3p were significantly increased in the serum and brain tissues of rats undergoing cerebral ischemia.In recent years,there is evidence of the protective capacity of the saponins extracted from panax ginseng and its primary active ingredient ginsenosideRg1oncerebral ischemic injury.Methods:Fetal rat neurons(FRNs)were cultured in glucose-and-serumfree medium and exposed to hypoxia to establish a cerebral ischemia model in vitro(oxygen and glucose deprivation model,OGD).Antioxidant indexes(CAT,SOD),inflammatory markers(MPO,TNF-αand IL-6),and the expression of apoptosis and proliferation associated proteins(NF kB-p65,Caspase 3-cleaved,BCL-2)were examined.Results:Pre-treatment of Rg1(30–100μg/mL)could effectively inhibit the decline of antioxidant indexes(CAT,SOD)and increase in inflammatory markers(MPO,TNF-αand IL-6),and effectively inhibited the apoptosis in FRNs induced by OGD in a gradient-dependent manner.The mechanism analysis showed that the role of Rg1 in protecting against ischemia-induced neuron damage depends on its indirect up-regulation of PPAR protein via suppression of rnomiRNA-27a-3p.Moreover,these effects of Rg1 could be reversed by exogenous rno-miRNA-27a-3p and PPAR gene silencing in FRNs exposed to OGD.Conclusion:To summarize,our study demonstrates that Rg1 could effectively attenuate neuronal damage caused by cerebral ischemia via the rno-miRNA-27a-3p/PPARγpathway.Further,clarification of the novel mechanism will certainly improve our previous understanding of the role of Rg1 and enhancing its level in treatments for alleviating ischemic brain injury.

Ginsenoside F1 administration promotes UCP1-dependent fat browning and ameliorates obesity-associated insulin resistance

Obesity-induced type 2 diabetes is mainly due to excessive free fatty acids leading to insulin resistance.Increasing thermogenesis is regarded as an effective strategy for hypolipidemia and hypoglycemia.Ginsenoside is a natural active component in Panax ginseng C.A.Meyer,and some of them enhance thermogenesis.However,there are few studies on the mechanism and target of ginsenosides enhancing thermogenesis.Using thermogenic protein uncoupling protein 1(UCP1)-luciferase reporter assay,we identifi ed ginsenoside F1 as a novel UCP1 activator in the ginsenosides library.Using pull down assay and inhibitor interference,we found F1 binds toβ3-adrenergic receptors(β3-AR)to enhance UCP1 expression via cAMP/PKA/CREB pathway.We also investigated the ability of F1 on energy metabolism in obesity-induced diabetic mice,including body weight,body composition and energy expenditure.The results of proteomics showed that F1 signifi cantly up-regulated thermogenesis proteins and lipolytic proteins,but down-regulated fatty acid synthesis proteins.Ginsenoside F1 increased thermogenesis and ameliorated insulin resistance specifi cally by promoting the browning of white adipose tissue in obese mice.Additionally,ginsenoside F1 improves norepinephrine-induced insulin resistance in adipocytes and hepatocytes,and shows a stronger mitochondria respiration ability than norepinephrine.These fi ndings suggest that ginsenoside F1 is a promising lead compound in the improvement of insulin resistance.

Protective effect of ginsenoside Rg1 on 661W cells exposed to oxygen-glucose deprivation/reperfusion via keap1/nrf2 pathway

AIM:To construct an in vitro model of oxygen-glucose deprivation/reperfusion(OGD/R)induced injury to the optic nerve and to study the oxidative damage mechanism of ischemia-reperfusion(I/R)injury in 661W cells and the protective effect of ginsenoside Rg1.METHODS:The 661W cells were treated with different concentrations of Na2S2O4 to establish OGD/R model in vitro.Apoptosis,intracellular reactive oxygen species(ROS)levels and superoxide dismutase(SOD)levels were measured at different time points during the reperfusion injury process.The injury model was pretreated with graded concentrations of ginsenoside Rg1.Real-time polymerase chain reaction(PCR)was used to measure the expression levels of cytochrome C(cyt C)/B-cell lymphoma-2(Bcl2)/Bcl2 associated protein X(Bax),heme oxygenase-1(HO-1),caspase9,nuclear factor erythroid 2-related factor 2(nrf2),kelch-like ECH-associated protein 1(keap1)and other genes.Western blot was used to detect the expression of nrf2,phosphorylated nrf2(pnrf2)and keap1 protein levels.RESULTS:Compared to the untreated group,the cell activity of 661W cells treated with Na2S2O4 for 6 and 8h decreased(P<0.01).Additionally,the ROS content increased and SOD levels decreased significantly(P<0.01).In contrast,treatment with ginsenoside Rg1 reversed the cell viability and SOD levels in comparison to the Na_(2)S_(2)O_(4)treated group(P<0.01).Moreover,Rg1 reduced the levels of caspase3,caspase9,and cyt C,while increasing the Bcl2/Bax level.These differences were all statistically significant(P<0.05).Western blot analysis showed no significant difference in the protein expression levels of keap1 and nrf2 with Rg1 treatment,however,Rg1 significantly increased the ratio of pnrf2/nrf2 protein expression compared to the Na_(2)S_(2)O_(4)treated group(P<0.001).CONCLUSION:The OGD/R process is induced in 661W cells using Na_(2)S_(2)O_(4).Rg1 inhibits OGD/R-induced oxidative damage and alleviates the extent of apoptosis in 661W cells through the keap1/nrf2 pathway.These results suggest a potential protective effect of Rg1 against retinal I/R injury.

人参皂苷Rb_(1)脂质体的制备及对脂肪细胞中脂滴积聚的抑制作用

[目的]制备β-谷甾醇修饰的人参皂苷Rb_(1)脂质体(β-Rb_(1)-Lip),减少Rb_(1)降解并增强人参皂苷Rb_(1)降脂效果。[方法]采用薄膜水和法制备了β-谷甾醇修饰的人参皂苷Rb_(1)脂质体,利用MTT法评估脂质体的生物安全性,借助油红O染色试验和酶标仪测量TG含量,考察了脂质体β-Rb_(1)-Lip对脂肪细胞3T3-L1的脂滴积聚抑制作用。[结果]制备的β-Rb_(1)-Lip脂质体的包封率为83.74%,平均粒径为198 nm,β-Rb_(1)-Lip在12 h内Rb_(1)释放率约为80%,表现出良好的缓释效果。对于降脂活性,50μmol/L的β-Rb_(1)-Lip表现出显著的细胞内脂滴抑制率,与同浓度Rb_(1)单体相比,β-Rb_(1)-Lip对3T3-L1细胞内脂滴的抑制效果更为显著,且对细胞没有毒副作用。[结论]β-Rb_(1)-Lip具有包封率高、粒径小和缓释效果明显的特征,能够持续释放活性成分人参皂苷Rb_(1),增强其降脂功效并减少用量。

HPLC法同时测定腰息痛胶囊中3种活性成分含量

目的 建立HPLC法同时测定腰息痛胶囊中的三七皂苷R_(1)、人参皂苷Rg_(1)、人参皂苷Rb_(1)的含量。方法 采用Omini MP C_(18)(4.6 mm×200 mm,5μm)为色谱柱;流动相为乙腈-0.1%磷酸溶液,梯度洗脱;流速为0.7 ml/min;检测波长为203 nm;柱温为25℃。结果 三七皂苷R_(1)、人参皂苷Rg_(1)、人参皂苷Rb_(1)分别在40.402~1010.500,40.480~1012.000,41.480~1037.000μg范围内呈线性关系(r<0.99);平均加样回收率分别为97.8%,97.5%,98.7%(RSD<2.0%,n=6);精密度、重复性等试验均符合规定。结论 此法简便易行、结果科学,可为中西药复方制剂腰息痛胶囊中的3种皂苷类成分定量控制提供技术依据。

人参皂苷Rg_1和Rh_1抗肿瘤作用的研究

目的 :研究人参皂苷 Rh1及其前体 Rg1的整体及离体抗肿瘤作用。方法 :整体实验 4种小鼠移植性肿瘤 :小鼠宫颈癌 - 1 4( U14 )、艾氏腹水癌 ( EAC)、肉瘤 - 1 80 ( S180 )和肝癌腹水型 ( Hep A)腋部皮下接种 ,于接种 1 0 d内 ,每天给药 1次 ,计算各给药组肿瘤抑制率。离体抗肿瘤实验用 3种瘤株 :A375 - S2、T98G 和 He La。结果 :人参皂苷 Rg1( 2 0 0 mg·kg-1,灌胃 )和 Rh1( 4 0和2 0 mg· kg-1,腹腔注射 )对 U14 均具有明显的抑制作用 ( P<0 .0 1 ) ;人参皂苷 Rh1在较高剂量( 4 0 mg·kg-1)时 ,对 EAC也有明显抑制作用 ( P<0 .0 1 )。但人参皂苷 Rg1和 Rh1对 S180 和 Hep A无抗肿瘤作用。离体实验证明 ,Rg1对 He La细胞的增殖有明显的抑制作用 ,Rh1高剂量组( 1 0 0 mg· L-1)对 3种肿瘤细胞均有明显抑制作用。结论 :人参皂苷 Rh1较其前体

人参皂苷Rg_1及其肠内菌代谢产物Rh_1对小鼠免疫细胞功能的影响

目的 初探人参皂苷Rg1 及其肠内菌代谢产物Rh1 对正常小鼠免疫功能的影响。方法 用Rh1 与Rg1 分别处理脾T细胞 ,B细胞及腹腔巨噬细胞 (Mφ) ;MTT比色法测T和B细胞增殖能力 ;中性红比色法测Mφ的吞噬功能 ;Griess法测Mφ释放NO的水平。 结果 Rh1 能促进脾细胞增殖、下调ConA诱导的T细胞增殖 ;Rh1 与Rg1 对LPS诱导的B细胞增殖均无明显作用 ;Rg1 和Rh1 能提高Mφ的吞噬能力和促进NO的释放。 结论 Rg1 及其代谢产物Rh1 可共同作用于T细胞和Mφ而产生免疫调节作用。

高效液相色谱法同时测定三七总皂苷中人参皂苷Rg_1、Re、Rb_1与三七皂苷R_1含量

目的建立高效液相色谱法同时测定三七总皂苷中人参皂苷Rg1、Re、Rb1与三七皂苷R1的方法。方法采用高效液相色谱法 ,固定相为氨基键合相 ,流动相为乙腈 水 ( 81∶1 9,V∶V) ,检测波长2 0 3nm。结果三七总皂苷中人参皂苷Rg1、Re、Rb1和三七皂苷R1与其他成分分离良好 ,保留时间分别约为 5 7min、8 9min、2 5 1min和 9 9min。人参皂苷Rg1在 80～ 2 80mg/L(r =0 9992 )、Re在 2 0～ 1 80mg/L(r=0 9993 )、Rb1在 95～ 2 85mg/L(r=0 9991 )、三七皂苷R1在1 8～ 1 4 6mg/L(r=0 9991 )内线性关系良好 ,人参皂苷Rg1、Re、Rb1和三七皂苷R1的回收率分别为 99 1 %、98 4 %、98 6%和 97 1 % ,RSD分别为 2 1 %、2 0 %、2 2 %、2 8%。

UPLC-MS/MS测定心悦胶囊中6个皂苷类成分的含量

目的:采用超高效液相色谱-质谱法(UPLC-MS/MS)建立心悦胶囊中主要成分人参皂苷Rg_(1)、人参皂苷Re、人参皂苷Rb_(1)、拟人参皂苷F_(11)、人参皂苷Rd和20(S)-人参皂苷F1的含量测定方法。方法:使用Waters ACQUITY BEH C_(18)色谱柱(100 mm×2.1 mm,1.7μm),以乙腈-水为流动相,梯度洗脱,流速为0.5 mL·min^(–1),柱温为40℃,电喷雾电离源,多反应离子监测扫描方式进行检测。结果:6个成分分别在质量浓度为9.638~963.800、9.839~983.900、9.951~995.100、5.270~1054.000、9.608~960.800、4.905~981.000 ng·mL^(–1)时与峰面积线性关系良好(r>0.998),平均加样回收率(RSD)分别为96.9%(2.2%)、100.1%(1.5%)、97.2%(1.8%)、98.5%(2.3%)、96.6%(2.8%)、100.2%(3.5%)。结论:所建立的方法快速、准确、灵敏度高,可用于心悦胶囊中西洋参茎叶总皂苷的质量控制。

肠内菌群对人参皂苷Rg_1的代谢转化作用的研究

目的 :通过离体和整体实验研究大鼠及人的肠道内细菌对人参皂苷Rg1的代谢作用。方法 :用薄层层析及电喷雾质谱检测Rg1的代谢产物。结果 :Rg1在大鼠体内被代谢成一对同分异构体 (Rh1及F1)及苷元 [2 0(S)Protopanaxatriol,Ppt]。但在人的肠道内 ,则代谢物为Rh1及苷元。结论 :Rg1在人和大鼠肠内菌作用下均被代谢 ,但沿不同的代谢途径进行代谢。在大鼠体内 ,代谢模式为 :Rg1Rh1(F1)Ppt ;在人体内 ,代谢模式为Rg1Rh1Ppt。

西洋参冠瘿组织培养及其人参皂苷Re和人参皂苷Rg_1的产生

考察了培养基组成、培养时间、接种量、pH值、肌醇浓度等对冠瘿组织生长及其人参皂苷含量的影响 ;用HPLC检测了冠瘿组织中人参皂苷Re和人参皂苷Rg1 的含量。高压纸层析电泳证实 ,根癌农杆菌Ti质粒上的T DNA片段已整合进入植物细胞核基因组中。在考察的 6种培养基中 ,White培养基最适合人参皂苷Rg1 的累积(0 0 95 % ) ,MS培养基最适合人参皂苷Re的累积 (0 194 % )。以MS为基本培养基培养 36d、32d时人参皂苷Re和人参皂苷Rg1 累积含量最高 (分别为 0 14 7%和 0 0 6 1% ) ;接种量为 4g、2g (FW flask) ,有利于人参皂苷Re和人参皂苷Rg1的累积 ;培养基pH 5 8时人参皂苷Re含量最高 (0 184 % ) ,培养基pH 5 6时人参皂苷Rg1 累积量最高 (0 0 5 4 % ) ;肌醇浓度为 0 0 5g L时 ,能促进人参皂苷Re合成 (0 182 % ) ,浓度为 0 30g L时 ,有利于人参皂苷Rg1 累积 (0 0 5 5 % )。

HPLC法同时测定三七总皂苷中人参皂苷Rg_1与Rb_1的含量

目的 建立 HPL C同时测定三七总皂苷中人参皂苷 Rg1 与 Rb1 的方法。方法 采用 HPL C法 ,以茶碱为内标 ,氨基键合相为固定相 ,流动相为乙腈 -水 (80∶ 2 0 ) ,检测波长 2 0 3nm。结果 三七总皂苷中人参皂苷 Rg1 和 Rb1与其他成分分离良好 ,保留时间分别约为 5 .7和 2 1.5 min。人参皂苷 Rg1 在 80～ 2 80μg/ m L (r=0 .9995 ) ,Rb1 在80～ 2 4 0 μg/ m L(r=0 .9993)线性关系良好 ,Rg1 和 Rb1 加样回收率分别为 97.1%和 98.4 %,RSD分别为 2 .4 4 %和 2 .35 %(n=9)。结论 本法操作简便 ,准确 ,重现性好 ,可用于人参及三七的质量控制。